THERAPY DOSSIER · th-06ccc3e29cdf

Deferoxamine mesylate, 2,3-dihydroxybenzoic acid, dimethyl sulfoxide, dimethylthiourea, sodium benzoate, vitamin E (and catalase)

Drug · Iron chelating agent (parent CHEMBL556). Only the deferoxamine component resolved; the other co-administered antioxidants/radical scavengers in this combination were not separately matched.

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: Iron chelating agent (parent CHEMBL556). Only the deferoxamine component resolved; the other co-administered antioxidants/radical scavengers in this combination were not separately matched.
Target: CHEMBL2363058
Injury models: Burn · TBI
Reported indication: Deferoxamine mesylate - iron overload (acute iron intoxication and chronic transfusional overload); the co-administered antioxidants are not separately approved as this combination
First approval: 1968
Development stage: Deferoxamine approved as iron chelator; ICH neuroprotection futile (i-DEF)
ChEMBL record: CHEMBL1234 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Desferal; Deferoxamine mesilate; Desferrioxamine mesylate; NSC-756718; BA-33112
Note: Not recorded

Clinical trials 11

4 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT06763055 ↗Injury indicationPHASE3recruiting

Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage trial within ACT-GLOBAL (deferoxamine mesylate arm)

Intracerebral Hemorrhage · Acute Stroke

Enrolment: 2000 · Results not recorded

NCT02175225 ↗Injury indicationPHASE2completed

Study of deferoxamine mesylate in intracerebral hemorrhage

Intracerebral Hemorrhage

Enrolment: 294 · Results not recorded

NCT01662895 ↗Injury indicationPHASE2terminated

Futility Study of Deferoxamine in Intracerebral Hemorrhage

Intracerebral Hemorrhage

Enrolment: 42 · Results not recorded

NCT02367248 ↗Injury indicationPHASE1/PHASE2unknown

Safety and Effectiveness of Deferoxamine and Xingnaojing Injection in Intracerebral Hemorrhage

Intracerebral Hemorrhage

Enrolment: 180 · Results not recorded

NCT00105495 ↗PHASE4completed

Deferiprone vs Deferoxamine in Removing Excess Cardiac Iron in Thalassemia Major

Thalassemia Major

Enrolment: 60 · Results not recorded

NCT06352632 ↗PHASE3recruiting

ACT-GLOBAL Adaptive Platform Trial for Stroke (incl. deferoxamine mesylate arm)

Stroke

Enrolment: 20000 · Results not recorded

NCT04361032 ↗PHASE3unknown

Tocilizumab Compared to Deferoxamine in COVID-19 Patients in Intensive Care

COVID19

Enrolment: 260 · Results not recorded

NCT01511848 ↗PHASE2/PHASE3unknown

Combined Deferiprone and Deferasirox Versus DFP and Desferrioxamine in Severe Iron Overload

Beta-thalassemia Major

Enrolment: 60 · Results not recorded

NCT01459718 ↗PHASE2terminated

Deferasirox in combination with deferoxamine followed by deferasirox monotherapy in beta-thalassemia with severe cardiac iron overload

Transfusion-dependent beta-thalassemia · Cardiac Iron Overload

Enrolment: 32 · Results not recorded

NCT00600938 ↗PHASE2completed

Deferasirox Compared With Deferoxamine in Cardiac Iron Overload Due to Chronic Blood Transfusions

Transfusional Iron Overload

Enrolment: 197 · Results not recorded

NCT01752153 ↗PHASE1completed

Immunomodulatory effects of silymarin in patients with beta-thalassemia major (desferrioxamine background therapy)

Immune Abnormalities

Enrolment: 25 · Results not recorded

Preclinical evidence 2

2 studies reported at therapy level; 2 evidence entries itemised.

PMID 2990218 ↗1985Reported benefit

Lipid peroxidation and acute lung injury after thermal trauma to skin. Evidence of a role for hydroxyl radical.

RatBurnUnspecifiedPretreatment (for the conjugated diene experiments)

Model: Thermal (burn) injury to the skin of rats producing remote acute lung injury

Iron chelators, hydroxyl radical scavengers and vitamin E each gave significant protection from acute lung injury measured by lung vascular permeability and morphology. Conjugated dienes appeared sequentially in burned skin at 15 minutes, lung at 2 hours and plasma at 30 minutes and 3 hours, and th…

Extraction: extract · Supplied extraction confidence: 0.78. Machine-extracted fields require source verification.

PMID 30343257 ↗2018Mixed findings

Neuroinflammation, oxidative stress, and blood-brain barrier (BBB) disruption in acute Utah electrode array implants and the effect of deferoxamine as an iron chelator on acute foreign body response.

RatTBIUnspecifiedSprague DawleyMalen = n=5 per group for the liver and kidney function safety test…Intraperitoneal100 mg/kg in sterile waterFirst injection one hour after implantation surgery

Model: Implantation of a non-functional 4 x 4 Utah microelectrode array into the somatosensory cortex, causing vascular and blood-brain barrier disruption and a foreign body response

Utah array implantation elicited acute oxidative stress, neuroinflammation and neurovascular unit disruption. Deferoxamine was evaluated as an iron chelator intended to reduce free iron in the parenchyma; the abstract reports the evaluation without stating a single overall direction of effect acros…

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…